Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
BioXcel Therapeutics, Inc. (BTAI) had Normalized Income after Taxes of $-59.60M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$2.27M |
|
$-59.60M |
|
$2.14M |
|
$0.12M |
|
$69.51M |
|
$-67.25M |
|
$7.65M |
|
$-59.60M |
|
$-59.60M |
|
$-59.60M |
|
$-59.60M |
|
$-59.60M |
|
|
Normalized Income after Taxes |
$-59.60M |
$-67.25M |
|
$-66.94M |
|
2.54M |
|
2.54M |
|
$-23.51 |
|
$-23.51 |
|
| Balance Sheet Financials | |
$37.39M |
|
$0.47M |
|
$0.94M |
|
$38.34M |
|
$22.23M |
|
$102.51M |
|
$109.21M |
|
$131.44M |
|
$-93.10M |
|
$-93.10M |
|
$-93.10M |
|
3.10M |
|
| Cash Flow Statement Financials | |
$-72.03M |
|
-- |
|
$36.66M |
|
$65.22M |
|
$29.85M |
|
$-35.37M |
|
$6.16M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.68 |
|
-- |
|
-- |
|
10.90 |
|
-1.10 |
|
5.43% |
|
-2967.56% |
|
-2967.56% |
|
-2953.93% |
|
-2630.14% |
|
-2630.14% |
|
$-72.03M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
3.16 |
|
17.30 |
|
21.10 |
|
64.02% |
|
64.02% |
|
-155.46% |
|
-633.56% |
|
$-30.01 |
|
$-28.41 |
|
$-28.41 |
|